Specifically, ApTOLL, an aptamer that antagonizes Toll-like receptor 4 (TLR4), was safe and associated with a reduction in mortality and disability at 90 days in patients with ischemic stroke in Phase I/II randomized clinical trial when administered within 6 h of onset in combination with endovascular treatment [116]. The gene discussed is TLR4; the disease is ischemic stroke.